ESC/EAS Guidelines on the Management of Dyslipidaemias (TF33) - TF Members and Additional Contributors

Transcription

1 ESC/EAS Guidelines on the Management of Dyslipidaemias (TF33) - TF Members and Additional Contributors Agewall Stefan - Astra Zeneca : Platelet inhibition Alegria Ezquerra Eduardo - Roche : dabigatran Catapano Alberico - Pfizer : cardiovascular - Sanofi Aventis : cardiovascular - Genzyme, Shire HGT : cardiovascular - AstraZeneca : cardiovascular - Merck Schering Plough : cardiovascular - Merck : basic research no direct link to products - AstraZeneca : epidemiology no direct link to products Chapman John - Pfizer Inc., New York : Autoimmune dyslipidemia - Merck : Cardiometabolic Disease - Roche Pharma : Cardiometabolic disease - Danone : Hypercholesterolemia - Kowa : Dyslipidemia - Merck : None De Backer Guy - Astra Zeneca - speaker fees : Crestor Durrington Paul No Erdine Serap - Boehringer-Ingelheim : Therapeutic Area - Daiichi Sankyo : Therapeutic Area - Novartis : Therapeutic Area

2 ESC/EAS Guidelines on the Management of Dyslipidaemias (TF33) - TF Members and Additional Contributors Erdine Serap - Abbott Laboratories : Therapeutic Area Graham Ian - Pfizer - speakers fees : CVD risk - MSD - speaker fee : CVD risk - MSD : Neither- audit of risk factor control - Pfizer : On-line guideline learning tool Halcox Julian - Pfizer : Cardiovascular Pharmacology - Abbott : CV Pharmacology - Astra Zeneca : CV Pharmacology - Boehringer-Ingelheim : CV Pharmacology - Servier : CV Pharmacology - Roche : CV Pharmacology - Sanofi Aventis : CV Pharmacology - Merck Sharp & Dohme : CV Pharmacology Hobbs Richard - Novartis : Hypertension - Astra Zeneca : Lipids, CV risk, Heart Failure - Pfizer : Lipids, CV risk,thrombosis, Heart Failure - MSD-SP, Boehringer Ingelheim, Bayer : Lipids, Diabetes - Bayer : Thrombosis - Boehringer-Ingelheim : Thrombosis Kjekshus John - Novartis : Transplantation - Schering-Plough : Vytorin

3 ESC/EAS Guidelines on the Management of Dyslipidaemias (TF33) - TF Members and Additional Contributors Kjekshus John - Servier : Ivabradin Perrone-Filardi Pasquale - Takeda : candesartan - Boheringer : dabigatran - Merck, Schering Plough : ezitimibe - Menarini : ranolazine - Astra zeneca : rosuvastatin E - Research funding (personal). - As a member of the TIMI Study Group I declare that our research group receives funding from a number of companies where I am not the PI. These include: Merck, BMS, Millennium, Nuvelo, Astra Zeneca, CV Therapeutics, Inotek, Schering-Plough, Integrated Ther : rivaroxaban, TIMI 50 Reiner Zeljko - Bayer Healthcare : anticoagulants Riccardi Gabriele - Astra Zeneca : antilipemics - Pfizer : antilipemics - Merck Sharp & Dohme : antilipemics - Abbott - lecture fees : antilipemics - Barilla : foods - Eli Lilly : insulin - Merck Sharp & Dohme : ezetimibe - Novo Nordisk : insulin Storey Robert Frederick - The Medicines Company : Cangrelor - Sanofi Aventis : Clopidogrel

4 ESC/EAS Guidelines on the Management of Dyslipidaemias (TF33) - TF Members and Additional Contributors Storey Robert Frederick - Bristol Myers Squibb : Clopidogrel - Novartis : Elinogrel - GlaxoSmithKline : Fondaparinux - Eli Lilly Lilly/Daiichi Sankyo - speakers fees; advisory board fees (prasugrel) : Prasugrel - Astra Zeneca : Ticagrelor - Merck : Vorapaxar - Astra Zeneca : Ticagrelor - Accumetrics : VerifyNow - Daiichi Sankyo : Prasugrel - Eli Lilly : Prasugrel - Astra Zeneca : Ticagrelor - Merck : Vorapaxar Taskinen Marja-Riitta - Roche Pharma, advisory board : CETP inhibitor - MSD - speaker fee : CETP inhibitor, tredaptive - Boehringer Ingelheim - consulting or lecture fees : DDP4 inhibitor - Kowa, consulting or lecture fees : Statins - MSD : CETP inhibitor - Takeda : DDP4 inhibitor - Eli Lilly : Exenatide - Novo Nordisk : No product Wiklund Olov - Pfizer - consulting or lecture fees : Atorvastatin - Merck - speaker fees : Ezetrol

5 ESC/EAS Guidelines on the Management of Dyslipidaemias (TF33) - TF Members and Additional Contributors Wiklund Olov - Astra Zeneca : Rousavstatin - Sanofi Aventis : Antidiabetics basal studies - Pfizer : Atorvastatin - Gambro : Dialysis equipment - Ethicon Endo Surgery GmbH : Endosurgical equipment - PPD Scand AB/Takeda : Glithazon clinical study - Biogaia : Probiotics in metabolism - AstraZeneca : Rousuvastatin, and basal cartdiovascular research Wood David Allan - Roche : Rheumatoid arthritis; Aleglitazar - Bayer Schering Pharma : 3rd ESC Asia CVD Symposium - Astra Zeneca : Crestor - Lipid Modification - Zentiva : Generic Drug Manufacturer - Merck Sharp & Dohme : Niacin - Lipid Modification - Chugai Pharma UK : Rheumatoid Arthritis - Pfizer : Vernicline - Smoking Cessation - Pfizer : Varenicline - Smoking Cessation

6 ESC/EAS Guidelines on the Management of Dyslipidaemias (TF33) - Document Reviewers Berkenboom Guy - Eli Lilly : antithrombotics - Astra zeneca : statins Descamps Olivier - Astra Zeneca : Crestor - Merck Sharp & Dohme : Inegy, Ezetrol, Zocor - Astra Zeneca : Crestor - Astra Zeneca : crestor Funck-Brentano Christian - Pierre-Fabre : Cardiac Safety of non-cardiovasclar products trials. - Servier : Cardiac safety of non-cardiovascular drugs under development or on the market. Design of phase I/II trials. - Johnson & Johnson : Cardiac safety of non-cardiovascular drugs under development or on the market. Design of phase I/II - Sigma-Tau (Italy) : Cardiac Safety of an antimalarial drug - MMV (CH) : Cardiac Safety of an antimalarial drug - Santhera (CH) : Cardiac Safety of an antimalarial drug - TROPHOS : DSMB for an investigational drug in Amyotrophic Lateral Sclerosis Cardiac safety - CEPHALON : DSMB in an oncology phase IIb trial - Jansen-Cilag : Proton-pump inhibitors and drug interactions, including Clopidogrel Jansen-Cilag : Proton-pump inhibitors and drug interactions with Clopidogrel Gotcheva Nina A - Direct Personal - payment: Speaker fees, Honoraria, Consultancy, Advisory Board fees, Investigator, Committee Member, etc. - Astra Zeneca - speaker fees : Atacand, Ticagrelore - Boehringer Ingelheim - : Dabigatran - Sanofi-Aventis : Dronedarone

7 ESC/EAS Guidelines on the Management of Dyslipidaemias (TF33) - Document Reviewers Gotcheva Nina - As a member of the TIMI Study Group I declare that our research group receives funding from a number of companies where I am not the PI. These include: Merck, BMS, Millennium, Nuvelo, Astra Zeneca, CV Therapeutics, Inotek, Schering-Plough, Integrated Ther : Rivaroxaban - Astra Zeneca : Ticagrelor - Actavis : Trimetazidine - As a member of the TIMI Study Group I declare that our research group receives funding from a number of companies where I am not the PI. These include: Merck, BMS, Millennium, Nuvelo, Astra Zeneca, CV Therapeutics, Inotek, Schering-Plough, Integrated Ther : Rivaroxaban Griffith Kathryne - Boehringer-Ingelheim : Atrial fibrillation and BP Guida Guido Francesco No - Takeda Pharmaceuticals : canesartan management of heart failure and CKD - Bristol Myers Squibb : hypertension and kidney disease - Merck Sharp & Dohme : lipid management Gulec Hasan Sadi - Pfizer : atorvastatin - Bayer : nifedipin - Astra Zeneca - speaker fees : rosuvastatin and candesartan - Glaxo Smith Kline : telmisartan - Boehringer Ingelheim - speaker fees : telmisartan - Menarini - speaker fees : zofenopril Henkin Yaakov - Merck Sharp & Dohme : Ezetimibe, Tredaptive - Pfizer : Lipitor - Merck Sharp & Dohme : IMPROVE-IT study Huber Kurt - Pfizer - speakers fees : atorvastatin

8 ESC/EAS Guidelines on the Management of Dyslipidaemias (TF33) - Document Reviewers Huber Kurt - The Medicines Company - speakers fees : bivalirudin; cangrelor - BRAHMS GmbH - speakers fees : copeptin assay - Boehringer Ingelheim - speakers fees; advisory board fees (dabigatran) : dabigatran - Boston Scientific - speakers fees : none - Biotronik - speakers fees : none - Eli Lilly Lilly/Daiichi Sankyo - speakers fees; advisory board fees (prasugrel) : prasugrel; abciximab - Bayer - speaker fees; advisory board fees (rivaroxaban) : rivaroxaban - Astra Zeneca - speakers fees; advisory board fees (ticagrelor) : ticagrelor; rosuvastatin Kesaniemi Antero - MSD : Hypolipidemic therary - Schering-Plough : Hypolipidemic therapy - Merck Schering Plough : Hypolipidemic therapy Lekakis John - GSK : Darapladib - MSD : Vorapaxar - GSK : Darapladib Manolis Athanasios John - Servier, Menarini, Abbot, Recordati, Omron, Bayer, GSK, : Hypertension, CHD,AF,CHF Marques-Vidal Pedro - Swiss Federal Office of Public Health : Consultant for National Nutritional Survey Masana Luis - Esteve : Lipids - MSD : Lipids - Danone : lipids

9 ESC/EAS Guidelines on the Management of Dyslipidaemias (TF33) - Document Reviewers Masana Luis - Kowa : lipids McMurray John - Novartis - consulting or lecture fees : NAVIGATOR/ASPIRE/ALTITUDE/PARADIGM-HF/VIVIDD studies - Sanofi Aventis - consulting or lecture fees : Lixisenatide CV study C - Receipt of royalties for intellectual property. - Bristol Myers Squibb : ARISTOTLE study - Amgen Inc : RED-HF/TREAT studies E - Research funding (personal). - F. Hoffman La Roche Ltd : ALECARDIO DSMS - Pfizer - consulting or lecture fees : EMPHASIS study - Glaxo Smith Kline : TIDE study Mendes Miguel Filipe - SanofiAventis : Dronedarone Pagava Zurab - Les Lab. Servier in Georgia : Spiaker fees - Novartis Pharma Services Group in Georgia : Spieker fees - Berlin-Chemie/MENARINI in Georgia : Spieker fees - Confidational : Investigator Pedersen Terje - Merck Sharp & Dohme - speaker fees : Lipids Poldermans Don - Astra Zeneca - speaker fee : Lipids C - Receipt of royalties for intellectual property. - Pfizer - speakers fees : Lipids - Maquette : Balloon pump device

10 ESC/EAS Guidelines on the Management of Dyslipidaemias (TF33) - Document Reviewers Poldermans Don - Merck : drugs Prescott Eva Rato Quiteria A Mateus Rosano Giuseppe M C Sans Menendez Susana No No No No - Novartis : drugs - Baxter : drugs - Medtronic : Reveal device Stalenhoef Anton - Genzyme, Shire HGT : cholesterol lowering - Merck Sharp & Dohme : cholesterol lowering Tokgozoglu Lale - Kowa : dyslipidemia - Abbott - lecture fees : dyslipidemia - Astra Zeneca, Bayer AG, Boehringer-Ingelheim, Daiichi-Sankyo, MSD, Novartis, Pfizer, Sanofi-Aventis, Servier : dyslipidemia, hypertension,antiplatelet,pulmonary hypertension - Servier : hypertension - Actelion - speaker fee : pulmonary hypertension Viigimaa Margus - Sanofi Aventis : Coagulation Wittekoek Janneke No - Glaxo Smith Kline : Coagulation - Servier : Coronary heart disease - Merck Sharp & Dome : Dyslipidemia - Menarini : Hypertension - Boehringer Ingelheim : Hypertension

11 ESC/EAS Guidelines on the Management of Dyslipidaemias (TF33) - Document Reviewers Zamorano Gomez Jose Luis De Graaf Jacqueline No - Daiichi Sankyo : Anticoagulation - Philips : Imaging - Merck : Lipids

12 ESC Committee for Practice Guidelines Auricchio Angelo Baumgartner Helmut Baumgartner Helmut Bax Jeroen - Biologics Delivery Systems, Cordis Corporation a Johnson & Johnson company : Biological Therapy - Philips : Cardiac Imaging - Merck : Drugs - Biotronik : Implantable Cardiac Electronic Device - EBR Systems : Implantable Cardiac Electronic Device - Impulse Dynamics : Implantable Cardiac Electronic Device - Medtronic : Implantable Cardiac Electronic Device - Sorin : Implantable Cardiac Electronic Device - St. Jude Medical : Implantable Cardiac Electronic Device - Abbott : Implantable Cardiac Electronic Device - Actelion : Bosentan for PAH treatment in congenital heart disease - AGA : Devices for catheter treatment of congenital heart defects - Edwards Lifesciences : transcatheter valve implantation - Heart.org : Education - Servier : Farma - Astra Zeneca : Farma - GE Healthcare : Imaging - Lantheus : Imaging - Philips : Imaging - St Jude Medical : Pacing

13 ESC Committee for Practice Guidelines Bax Jeroen Ceconi Claudio Deaton M Christi Deaton M Christi Fagard Robert Funck-Brentano Christian - Medtronic : Pacing - Impulse Dynamics : Pacing - Biotronik : Pacing - Boston Scientific : Pacing - Servier : Farma - Edwards Lifesciences : Heart Valves - Lantheus : Imaging - GE Healthcare : Imaging - Boston Scientific : Pacing - Medtronic : Pacing - St Jude Medical : Pacing - Biotronik : Pacing - Servier : Pharmaceutical - St Jude Ltd : Cath lab - speaker X 1 - Daiichi Sankyo : consultant for patient adherence Eli Lilly : consultant for patient adherence Novo Nordisk : medicines for diabetes - Servier : perindopril; support for organisation of scientific meeting - Pierre-Fabre : Cardiac Safety of non-cardiovasclar products

14 ESC Committee for Practice Guidelines Funck-Brentano Christian Hasdai David Hoes Arno Knuuti Juhani Knuuti Juhani Kolh Philippe H - Servier : Cardiac safety of non-cardiovascular drugs under development or on the market. Design of phase I/II trials. - Johnson & Johnson : Cardiac safety of non-cardiovascular drugs under development or on the market. Design of phase I/II trials. - Sigma-Tau (Italy) : Cardiac Saftey of an antimalarial drug - Santhera (CH) : Cardiac Saftey of an antimalarial drug - MMV (CH) : Cardiac Saftey of an antimalarial drug - TROPHOS : DSMB for an investigational drug in Amyotrophic Lateral Sclerosis Cardiac safety - CEPHALON : DSMB in an oncology phase IIb trial - Jansen-Cilag : Proton-pump inhibitors and drug interactions, including Clopidogrel - Jansen-Cilag : Proton-pump inhibitors and drug interactions with Clopidogrel - Sanofi Aventis : Enoxaparin - Bayer Healthcare : unresctricted grant for diagnostic kits in suspected cardiovascualar disease - Abbott Laboratories : unresctricted grant for diagnostic kits in suspected cardiovascualar disease - Roche : unresctricted grant for diagnostic kits in suspected heart failure and acute coronary syndrome - Lantheus Inc : Imaging tracers - Bayer : Development of imaging agents - GE Healthcare : Development of imaging agents - Lantheus : Development of imaging agents - Novartis : Development of imaging agents - Roche : Drugs for brain diseases

15 ESC Committee for Practice Guidelines Kolh Philippe H Kolh Philippe H McDonagh Theresa McDonagh Theresa McDonagh Theresa Poldermans Don - Merck Sharp & Dohme : Antiarrhythmic agents - Bristol Myers Squibb : Antiplatelet agents - Astra Zeneca : Antiplatelet agents - Regado Biosciences : Antithrombotic agents - Abbott - lecture fees : coronary stents - Merck Sharp & Dohme : Antistaphylococcic vaccine - Edwards Lifesciences : Cardiac valves - Medtronic : Cardiac valves - St Jude Medical : Cardiac valves - Siemens Healthcare : Imaging - Johnson & Johnson : Thoracoscopic devices - Vifor International : Ferrinject - Servier - speaker fee : Ivabridine - Biotronik - Clinical Trial : CRT - Maquette : Balloon pump device - Merck : drugs - Novartis : drugs - Baxter : drugs - Medtronic : Reveal device

16 ESC Committee for Practice Guidelines Popescu Bogdan Alexandru Reiner Zeljko Sechtem Udo Sechtem Udo Sirnes Per Anton - GE Healthcare : Imaging - Bayer Healthcare : anticoagulants - Abbott - lecture fees : antilipemics - Astra Zeneca : antilipemics - Merck Sharp & Dohme : antilipemics - Pfizer : antilipemics - Boehringer Ingelheim : Anticoagulation - Daiichi Sankyo : Antiplatelet therapy - Novartis : Drugs - General Electric : Imaging - Siemens Healthcare : Imaging - Novartis : Imaging devices - Johnson & Johnson : Stents - Bayer : clinical studies atrial fibrillation investigator fee - Johnson & Johnson : inestigator fee, ckinical study, atrial fibrillation - MSD : investgator fee clinical studies hyperlipidemia, SCAD - Glaxo Smith Kline : investigator fee, clinical study, SCAD - Servier : investigator fee, clinical study, coronary artery disease - Jansen-Cilag : investigator fee, clinical study, diabetes CVD - Boehringer Ingelheim : investigator fee, clinicla study, AF

17 ESC Committee for Practice Guidelines Torbicki Adam Vahanian Alec Windecker Stephan Windecker Stephan - Boehringer-Ingelheim : anticoagulation - Sanofi Aventis : anticoagulation - Pfizer : anticoagulation, pulmonary hypertension - Lilly : pulmonary hypertension - Actelion : pulmonary hypertension - Bayer Healthcare : pulmonary hypertension, anticoagulation - Boehringer Ingelheim : Valve prostheses - Siemens Healthcare : Valve prostheses - Valtech : Valve prostheses - Edwards Lifesciences : Valve prostheses - Abbott : Valve prostheses - Medtronic - Advisory Board : Valve prostheses - Astra Zeneca : Antiplatelet drug - Eli Lilly : Antiplatelet drug - Abbott : Stent - Biosensors : Stent - Biotronik : Stent - Boston Scientific : Stent - Cordis : Stent - Medtronic : Stent - Medtronic : Stent

18 ESC Committee for Practice Guidelines Abbott : Stent - Biosensors : Stent - Cordis : Stent This table represents the relevant relationships of the above experts and other entities that were reported to us at the time of publication of the guidelines.